{{Cite journal| doi = 10.1007/s41669-019-0157-9| issn = 2509-4254| volume = 4| issue = 1| pages = 45–60| last1 = Boyer| first1 = Sylvie| last2 = Nishimwe| first2 = M. L.| last3 = Sagaon-Teyssier| first3 = L.| last4 = March| first4 = L.| last5 = Koulla-Shiro| first5 = S.| last6 = Bousmah| first6 = Marwân-Al-Qays| last7 = Toby| first7 = R.| last8 = Mpoudi-Etame| first8 = M. P.| last9 = Ngom Gueye| first9 = N. F.| last10 = Sawadogo| first10 = A.| last11 = Kouanfack| first11 = C.| last12 = Ciaffi| first12 = L.| last13 = Spire| first13 = B.| last14 = Delaporte| first14 = E.| last15 = 2-Lady Group| title = Cost-effectiveness of three alternative boosted protease inhibitor-based second-line regimens in HIV-infected patients in West and Central Africa| journal = PharmacoEconomics - Open| date = 2020}}